The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial

Simon Rule, 1 Paul Smith, 2 Peter W.M. Johnson, 3 Simon Bolam, 4 George Follows, 5 Joanne Gambell, 2 Peter Hillmen, 6 Andrew Jack, 7 Stephen Johnson, 4 Amy A Kirkwood, 2 Anton Kruger, 8 Christopher Pocock, 9 John F. Seymour, 10 Milena Toncheva, 2 Jan Walewski 11 and David Linch 12

1Derriford Hospital, Plymouth, UK; 2Cancer Research UK and UCL Cancer Trials Centre, London, UK; 3University of Southampton, Southampton, UK; 4Musgrove Park Hospital, Taunton, UK; 5Addenbrookes Hospital, Cambridge, UK; 6St. James’s University Hospital, Leeds, UK; 7HMD, Leeds General Infirmary, UK; 8Royal Cornwall Hospital, Truro, UK; 9Kent and Canterbury Hospital, Canterbury, UK; 10The Peter MacCallum Cancer Centre, Melbourne, Australia; 11Maria Sklodowska-Curie Institute and Oncology Centre, Gilwice, Poland; and 12UCL Cancer Institute, London, UK

©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.128710

Received: 9/4/2015.
Accepted: 19/11/2015.
Pre-published: 26/11/2015.
Correspondence: eng2@nhlbi.nih.gov
At least one complete cycle

Two patients received FC cycles 2-8, one FC on cycles 2-6 and one 2-4

All patients were included in the main intention to treat analysis.

A complete cycle was classified as a cycle which included at least one dose of each drug.